Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 -0.88%91 ROC (Joel Greenblatt) % is 65.66% as of Jun. 2026, which is 6% above its 10-year median of 61.66. GuruFocus rates BOM:543904 with a GF Score™ of 91/100 and a GF Value™ of ₹2,974.38 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 982 Drug Manufacturers companies, Mankind Pharma ranks better than 88.19% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Mankind Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 65.66%.
The historical rank and industry rank for Mankind Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:
BOM:543904'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43.5 Med: 61.66 Max: 67.42
Current: 61.14
During the past 7 years, Mankind Pharma's highest ROC (Joel Greenblatt) % was 67.42%. The lowest was 43.50%. And the median was 61.66%.
BOM:543904's ROC (Joel Greenblatt) % is ranked better than 88.19% of 982
companies
in the Drug Manufacturers industry
Industry Median: 10.525
vs BOM:543904: 61.14
Mankind Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -1.70% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Mankind Pharma ROC (Joel Greenblatt) % Related Terms
Mankind Pharma ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543904 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 65.66% mean?
Mankind Pharma (BOM:543904) has a ROC (Joel Greenblatt) % of 65.66% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mankind Pharma and its competitors. This is near median its historical median of 61.66. Over the past decade, Mankind Pharma's ROC (Joel Greenblatt) % has ranged from 43.50 to 67.42. According to the industry distribution chart, Mankind Pharma ranks #116 out of 982 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is Mankind Pharma's ROC (Joel Greenblatt) % too high?
Mankind Pharma's current ROC (Joel Greenblatt) % of 65.66% is near median its 10-year median of 61.66. Over the past 10 years, this metric has ranged from a low of 43.50 to a high of 67.42. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 10.53. Mankind Pharma's value of 65.66% is 523.8% above this industry median. Based on the distribution chart, Mankind Pharma ranks #116 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mankind Pharma has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #116 out of 982 companies for ROC (Joel Greenblatt) %. This places Mankind Pharma in the top 12% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 10.53. Mankind Pharma's value of 65.66% is 523.8% above this benchmark. Historically, Mankind Pharma's own ROC (Joel Greenblatt) % has ranged from 43.50 to 67.42 over the past decade. While the company's 10-year median is 61.66 vs. the industry median of 10.53, Mankind Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.53, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current ROC (Joel Greenblatt) % of 65.66% is 523.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current ROC (Joel Greenblatt) % is 65.66%, which is near median its own 10-year median of 61.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,974.38, compared to a current price of ₹2,246.00 — trading 24.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 65.66%, which is near median its 10-year median of 61.66 and 523.8% above the Drug Manufacturers industry median of 10.53. Mankind Pharma's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current ROC (Joel Greenblatt) % is 65.66% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,246.00 is trading 24.5% below its estimated GF Value™ of ₹2,974.38.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
ROC (Joel Greenblatt) %: 65.66% (near median its 10-year median of 61.66)
GF Value™: ₹2,974.38 vs. price of ₹2,246.00 (24.5% below fair value)
Industry Position: 523.8% above the Drug Manufacturers median (#116 of 982)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
91GF Score
Get the complete analysis for BOM:543904
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
